Elicio Therapeutics (NASDAQ: ELTX) — Perfil da empresa, notícias e dados financeiros
Elicio Therapeutics develops vaccine and immunotherapy technologies to improve cancer treatment.
Elicio Therapeutics
Elicio Therapeutics (NASDAQ:ELTX) is dedicated to advancing vaccine and immunotherapy technologies for treating cancer and other serious diseases. Operating from its base, Elicio focuses on developing a robust pipeline of products aimed at eliciting potent immune responses targeted specifically at disease sites. Their projects integrate cutting-edge research in amphiphile technology to design therapies that precisely activate the immune system, promising a new era of precision medicine. Elicio's objectives are centered on transforming the landscape of cancer treatment, making therapies more effective and accessible to patients globally. Through continuous innovation and strategic collaboration, Elicio strives to achieve breakthroughs that will redefine standards of care in immuno-oncology.
Resumo
Operações
Produtos e/ou serviços de Elicio Therapeutics
- Immunotherapy Research & Development: Elicio focuses on researching and developing ELI-002, a vaccine targeting mKRAS mutations in cancer, and potentially other similar therapies in the future.
- Clinical Trial Management: Elicio conducts and manages clinical trials to test the safety and efficacy of their drug candidates like ELI-002.
- Collaboration with Research Institutions: Elicio might collaborate with research institutions for further development of their therapies or technologies.
- Data Analysis & Reporting: They analyze data from clinical trials and report the findings to regulatory agencies and the scientific community.
- Investor Relations & Communication: Elicio communicates with investors regarding their progress and developments.
- Technology Development: They work on developing and improving their Elicio AMP Technology platform for creating new immunotherapies.
equipe executiva do Elicio Therapeutics
- Robert T. ConnellyCEO, President & Director
- Allen Richard NissensonFounder & Independent Director
- Preetam ShahChief Strategy & Financial Officer and Treasurer
- Christopher M. HaqqExecutive VP, Head of Research & Development and Chief Medical Officer
- Darrell J. IrvineCo-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board
- Marc J. WolfgangChief Technology Officer
- Peter DeMuthChief Scientific Officer
- Megan C. FiloonGeneral Counsel, Secretary & Compliance Officer
- Esther WelkowskySenior Vice President of Clinical Development
- Joy SeymourSenior VP & Head of Regulatory Affairs
Últimas notícias sobre a Elicio Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Elicio Therapeutics, em USD.
- Cap. de mercado
- 50,1 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -2.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -37,7 mi | -39,6 mi | |
| 0 | -45 mi | -51,9 mi | |
| 0 | -35,7 mi | -35,2 mi | |
| 0 | -23,7 mi | -28,2 mi |